ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

U.S. Breast Cancer Death Rate Declines.

September 28, 2007

Study Of Tamoxifen And Raloxifene Enrolls 6,000 In First Year; 5 Percent Are Minorities

July 28, 2000

Three Nutrition RFPs withdrawn Due To “Vagueness”

July 8, 1977

Is Everyone in Academic Medicine Unhappy? Or is it Just MD Anderson?

December 12, 2014

NIH Recovery Act Announcements

March 27, 2009

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002